<h4>Aim</h4>The aim was to carry out a preliminary investigation to identify new biomarkers and test the suitability of the pro-inflammatory nuclear protein, HMGB1, as a potential diagnostic or treatment target for DCM.<h4>Background</h4>Diabetic cardiomyopathy (DCM) is a complex metabolic disease group which manifests in persons diagnosed with poorly managed <i>Diabetes mellitus</i>. Here, HMGB1 is linked to diabetes mellitus.